Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

HSP90 inhibition by RGRN-305 and 17-AAG decreased proinflammatory protein secretion. by Hakim Ben Abdallah (14578241)

ABT199 inhibits ALK ^mutant kinase activity and decreases it phosphorylation. by Richard Junior Zapata Dongo (17912565)

Subjects:

Raw data. by Saeedeh Abbasi (9423189)

Subjects:

Mean (95% CI) and standard deviation of Lumbar Lordosis angle(˚) between two groups pre and post 60 minutes of standing. by Saeedeh Abbasi (9423189)

Subjects:

Mean (95% CI) and standard deviation of VAS Score (mm) before & after intervention between two group during 1-houre standing. Intervention: using footrest with/without changing arm... by Saeedeh Abbasi (9423189)

Subjects:

Data. by Saeedeh Abbasi (9423189)

Subjects:

Co-Contraction index of right and left gluteus medius activity (MVC%) during 60 minutes standing (time- condition) between two groups (A: used the footrest intermittently, B: used... by Saeedeh Abbasi (9423189)

Subjects:

Example of a participant using the elevated surface (20 cm) during the intermittent footrest use (A) and the intermittent footrest use with arm flexion, hands crossed on the clavic... by Saeedeh Abbasi (9423189)

Subjects:

VAS score (mm) before & after intervention between two group (A: used the footrest intermittently, B: used the footrest with change arm positions) every 15 minutes during 60 minute... by Saeedeh Abbasi (9423189)

Subjects:

Mean (95% CI) and standard deviation of Co-Contraction index of right and left gluteus medius (MVC%) during 60 minutes standing between two groups. by Saeedeh Abbasi (9423189)

Subjects:

Reduction factor in different plant parts after exposure (14 days). by Yelena Polivkina (14341291)

Subjects:

Decreased hypotaurine levels within cells lacking the ADO gene in U251 cells. by Hong Tian (169626)

MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects: